A landmark shift in women's health terminology addresses decades of medical confusion and patient stigma. The condition affecting one in eight women worldwide will transition from polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), following an unprecedented global consensus involving over 14,000 stakeholders across six continents.
The collaborative effort, published in The Lancet, engaged 56 leading academic, clinical, and patient organizations through iterative surveys, modified Delphi methods, and nominal group workshops. The consensus prioritized scientific accuracy over familiarity, recognizing that the original PCOS terminology misleadingly suggested pathological cysts while obscuring the condition's complex endocrine and metabolic dysfunction. The new nomenclature explicitly captures the multisystem nature involving hormonal imbalances, insulin resistance, and reproductive irregularities.
This represents more than semantic updating—it reflects evolving understanding of a condition long fragmented across medical specialties. The misnomer 'polycystic' historically focused attention on ovarian appearance rather than underlying metabolic dysfunction, potentially delaying appropriate treatment approaches addressing insulin sensitivity, cardiovascular risk, and hormonal regulation. The global stakeholder process, including extensive patient input, suggests growing recognition that nomenclature shapes clinical priorities and research funding allocation. While implementation challenges remain substantial—requiring updates across medical education, insurance coding, and patient resources—the consensus demonstrates unprecedented coordination in women's health advocacy. This methodical rebranding may establish a template for addressing other medical terminology that inadequately reflects current pathophysiological understanding.